ARCT Q4 2021 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

$217M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+158.9% YoY

Gross Profit

-$25M-430.4% margin

Operating Income

-$38M-649.7% margin

Net Income

-$39M-667.3% margin

EPS (Diluted)

$-1.47

QoQ Revenue Growth

+137.8%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$44M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$393M

Total Liabilities

$165M

Stockholders' Equity

$228M

Cash & Equivalents

$370M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$2M	+158.9%
Gross Profit	-$25M	-$20M	-23.8%
Operating Income	-$38M	-$31M	-21.1%
Net Income	-$39M	-$31M	-24.3%